Teva Gets Tentative FDA Nod for Generic Aciphex

Drug is a generic version of Japanese company Eisai Co's acid pump inhibitor Aciphex tablets

Reuters
Reuters
Send in e-mailSend in e-mail
Reuters
Reuters

Teva Pharmaceutical Industries said on Thursday it was granted tentative U.S. Food and Drug Administration approval for Rabeprazole Sodium delayed-release tablets.

The drug is a generic version of Japanese company Eisai Co.'s acid pump inhibitor Aciphex tablets.

Annual sales of the branded product are about $1.2 billion, Teva said in a statement.

Teva, the world's largest generic drugmaker, said it was currently in patent litigation regarding the product in the U.S. District Court for the Southern Disctrict of New York.

A suit was brought against Teva in November of 2003 involving the product's patent. A trial date has not been set.

Final approval is expected upon a favourable decision in the case or the expiry of the mandatory stay of approval in February 2007, whichever is earlier.

Teva stock from 2004

Comments

SUBSCRIBERS JOIN THE CONVERSATION FASTER

Automatic approval of subscriber comments.

NOW: 40% OFF
Already signed up? LOG IN

ICYMI

הקלטות מעוז

Jewish Law Above All: Recordings Reveal Far-right MK's Plan to Turn Israel Into Theocracy

איתמר בן גביר

Why I’m Turning My Back on My Jewish Identity

Travelers looking at the Departures board at Ben Gurion Airport. The number of olim who later become yordim is unknown.

Down and Out: Why These New Immigrants Ended Up Leaving Israel

Beatrice Grannò and Simona Tabasco as Mia and Lucia in "The White Lotus."

The Reality Behind ‘The White Lotus’ Sex Work Fantasy

The Mossad hit team in Dubai. Exposed by dozens of security cameras

This ‘Dystopian’ Cyber Firm Could Have Saved Mossad Assassins From Exposure

מליאת הכנסת 28.12.22

Comeback Kid: How Netanyahu Took Back Power After 18 Months in Exile